Corporate News     26-Oct-20
Alembic Pharmaceuticals receives final USFDA approval for Timolol Maleate Timolol Maleate Ophthalmic Gel Forming Solution
Alembic Pharmaceuticals announced it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% and 0.5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Timoptic-XE Ophthalmic Gel Forming Solution, 0.25% and 0.5%, of Bausch Health US, LLC. Timolol Maleate Ophthalmic Gel Forming Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Alembic has been granted a Competitive Generic Therapies (CGT) designation for this ANDA and it is eligible for 180 days of . CGT exclusivity as it is the first approved ANDA.

Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% and 0.5% has an estimated market size of US$ 71 million for twelve months ending June 2020 according to IQVIA.

This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies.

Alembic has a cumulative total of 134 ANDA approvals (117 final approvals and 17 tentative approvals) from USFDA.

Previous News
  Alembic Pharmaceuticals receives USFDA approval for various products
 ( Corporate News - 09-May-24   09:01 )
  Alembic Pharmaceuticals receives EIR for its oncology unit at Panelav
 ( Corporate News - 06-May-24   08:52 )
  Alembic Pharmaceuticals consolidated net profit declines 29.03% in the December 2022 quarter
 ( Results - Announcements 01-Feb-23   17:10 )
  Alembic Pharmaceuticals receives USFDA approval for Prazosin Hydrochloride Capsules
 ( Corporate News - 08-Mar-23   09:14 )
  Volumes spurt at Alembic Pharmaceuticals Ltd counter
 ( Hot Pursuit - 08-Jun-23   14:30 )
  Volumes spurt at One 97 Communications Ltd counter
 ( Hot Pursuit - 08-Jun-23   11:00 )
  Alembic Pharmaceuticals to table results
 ( Corporate News - 22-Jul-23   11:01 )
  Alembic Pharma gets USFDA final approval for Prazosin Hydrochloride capsules
 ( Hot Pursuit - 08-Mar-23   09:19 )
  Alembic Pharma records 48% growth in Q3 PAT
 ( Hot Pursuit - 05-Feb-24   16:29 )
  Board of Alembic Pharmaceuticals recommends Interim dividend
 ( Corporate News - 05-Aug-22   10:48 )
  Alembic Pharmaceuticals receives USFDA approval for Dabigatran Etexilate Capsules
 ( Corporate News - 07-Apr-22   13:53 )
Other Stories
  Board of Delhivery approves alteration in capital clause of MoA
  05-Jul-24   19:32
  J B Chemicals & Pharmaceuticals appoints director
  05-Jul-24   19:30
  Infosys announces resignation of senior management personnel
  05-Jul-24   19:22
  JLR Q1 FY25 retail sales up 9% on YoY basis
  05-Jul-24   19:08
  Bajaj Auto launches world's first CNG motorcycle 'Freedom'
  05-Jul-24   18:59
  Agenda for board meeting of Power Grid Corporation of India
  05-Jul-24   18:46
  Board of Bank of Baroda approves raising additional capital up to Rs 7,500 cr in FY25
  05-Jul-24   18:06
  Vipul to hold board meeting
  05-Jul-24   17:15
  Markobenz Ventures to convene board meeting
  05-Jul-24   17:15
  Dhanashree Electronics to declare Quarterly Result
  05-Jul-24   17:15
Back Top